Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-011896
Filing Date
2024-08-12
Accepted
2024-08-12 16:05:32
Documents
77
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q aeon-20240630x10q.htm   iXBRL 10-Q 2813198
2 EX-31.1 aeon-20240630xex31d1.htm EX-31.1 16180
3 EX-32.1 aeon-20240630xex32d1.htm EX-32.1 9161
  Complete submission text file 0001558370-24-011896.txt   9638267

Data Files

Seq Description Document Type Size
4 EX-101.SCH aeon-20240630.xsd EX-101.SCH 73664
5 EX-101.CAL aeon-20240630_cal.xml EX-101.CAL 41037
6 EX-101.DEF aeon-20240630_def.xml EX-101.DEF 336104
7 EX-101.LAB aeon-20240630_lab.xml EX-101.LAB 553644
8 EX-101.PRE aeon-20240630_pre.xml EX-101.PRE 477784
80 EXTRACTED XBRL INSTANCE DOCUMENT aeon-20240630x10q_htm.xml XML 1419403
Mailing Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614
Business Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614 (949) 354-6499
AEON Biopharma, Inc. (Filer) CIK: 0001837607 (see all company filings)

EIN.: 853940478 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40021 | Film No.: 241196739
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)